Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DOYP92
|
|||
| Drug Name |
V937
|
|||
| Drug Type |
Vaccine
|
|||
| Indication | Melanoma [ICD-11: 2C30; ICD-9: 172] | Phase 2 | [1] | |
| Company |
Merck
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04152863) Efficacy, Safety, and Tolerability of V937 Administered Intravenously or Intratumorally With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone in Participants With Advanced/Metastatic Melanoma (V937-011). U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.